← Browse by Condition
Medical Condition
lymphoma non hodgkin
Total Trials
7
Recruiting Now
7
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — lymphoma non hodgkin Clinical Trials
How many clinical trials are currently recruiting for lymphoma non hodgkin?
ClinicalMetric currently tracks 7 actively recruiting clinical trials for lymphoma non hodgkin, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 7. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for lymphoma non hodgkin?
lymphoma non hodgkin research spans Phase 1 (4 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a lymphoma non hodgkin clinical trial?
Eligibility criteria for lymphoma non hodgkin trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 4
Phase 2 3
Top Sponsors
1 trial
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT06458439 Phase 2
Recruiting
Enrollment
31 pts
Location
United States
Sponsor
Abramson Cancer Center at Penn...
NCT07082803 Phase 1
Recruiting
Enrollment
180 pts
Location
United States, Austr...
Sponsor
Treeline Biosciences, Inc.
NCT06022029 Phase 1
Recruiting
Enrollment
168 pts
Location
United States, Austr...
Sponsor
OncoNano Medicine, Inc.
NCT06133426
Recruiting
Enrollment
30 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
NCT06541327
Recruiting
Enrollment
1,000 pts
Location
China
Sponsor
Ruijin Hospital
NCT06343311 Phase 1, Phase 2
Recruiting
Enrollment
27 pts
Location
United States
Sponsor
Estrella Immunopharma, Inc.
NCT07519772 Phase 1, Phase 2
Recruiting
Enrollment
280 pts
Location
United States, Argen...
Sponsor
Merck Sharp & Dohme LLC
Related Conditions
high grade b cell lymphoma (2) lymphoma (2) relapsed diffuse large b cell lymphoma (1) refractory diffuse large b cell lymphoma (1) transformed indolent non hodgkin lymphoma to diffuse large b cell lymphoma (1) triple negative breast cancer (1) diffuse large b cell lymphoma (1) follicular lymphoma (1) mantle cell lymphoma (1) bladder cancer (1) uveal melanoma recurrent (1) cervix cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology